𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation

✍ Scribed by Todd Brusko; Jeffrey Bluestone

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
147 KB
Volume
38
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Immune regulation is a complex process that depends on the maintenance of self tolerance while retaining robust immune responses against microbes. The emergence of Treg as a central mechanism for immune regulation has generated a new paradigm where Treg‐resistant memory T cells and/or “defective” Treg lead to a breakdown in tolerance resulting in immune pathology. In this perspective, we highlight the opportunities and challenges in the field of Treg therapy.

See accompanying commentary: http://dx.doi.org/10.1002/eji.200738107

📜 SIMILAR VOLUMES

Clinical application of NKT cell assays
Clinical application of NKT cell assays to the prediction of type 1 diabetes
✍ Lynn D. Poulton; Alan G. Baxter 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

## Abstract Type 1 diabetes is a disease characterised by disturbed glucose homeostasis, which results from autoimmune destruction of the insulin‐producing beta cells in the pancreas. The autoimmune attack, while not yet fully characterised, exhibits components of both mis‐targeting and failed tole

Anti-CD3 mAbs for treatment of type 1 di
Anti-CD3 mAbs for treatment of type 1 diabetes
✍ Adam Kaufman; Kevan C. Herold 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

## Abstract The use of anti‐CD3 monoclonal antibodies (mAbs) has moved from the bench to the bedside. The experience with the anti‐human CD3 mAb OKT3 for treatment of transplant rejection identified limitations that were largely overcome with the creation of humanized non‐FcR binding antibodies: Te

Regulatory T cells enter the pancreas du
Regulatory T cells enter the pancreas during suppression of type 1 diabetes and inhibit effector T cells and macrophages in a TGF-β-dependent manner
✍ Daniel R. Tonkin; Kathryn Haskins 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 364 KB

## Abstract Treg can suppress autoimmune diseases such as type 1 diabetes, but their __in vivo__ activity during suppression remains poorly characterized. In type 1 diabetes, Treg activity has been demonstrated in the pancreatic lymph node, but little has been studied in the pancreas, the site of a